Moffitt Notice of Blackbaud Data Incident. Learn More
Clinical Trials Search
A Multicenter, Randomized, Double Blinded, Placebo Controlled, Phase 3 trial of Adjuvant Avelumab (anti PDL1 antibody) in Merkel Cell Carcinoma Patients with Clinically Detected Lymph Node Metastases
The primary objective of the trial is to compare the clinical activity of adjuvant avelumab to that of placebo, as determined by relapse]free survival in subjects with clinically detected nodal metastases from MCC after definitive therapy (surgery with/without adjuvant RT).
Avelumab (); MSB00100718C (Avelumab); Placebo ()